maybe MSB had the conditions. Maybe SI didn’t reveal more than what NOVARTIS would be paying to hear.
I firmly believe SI wasn’t going to sell the shareholders out to Novartis. Some might call it stubborn. So be it. SI knows what our products are worth.
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain, page-111
-
- There are more pages in this discussion • 298 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
-0.005(0.36%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $4.391M | 3.156M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 48253 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 32922 | 2 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |